ClinicalTrials.gg
CompletedNCT03853694CHOICEUpdated Jul 18, 2022Results posted

Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section

A Phase 4 interventional study of 50 mcg Duramorph+ EXPAREL + multi-modal pain regimen and 150 mcg Duramorph + multi-modal pain regimen in Elective Cesarean Section and Pain Management, sponsored by Pacira Pharmaceuticals, Inc. Completed at 18 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-18.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
167
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this study is to compare total opioid consumption by subjects in different treatment groups.

Another purpose of this study is to assess how well EXPAREL works, collect any safety data and assess your satisfaction using EXPAREL.

Read the detailed description

This is a Phase-4, multicenter, randomized, active-controlled study in approximately 182 adult women undergoing elective C-section. All subjects will remain in the hospital for up to 72 hours post surgery.

Subjects will be screened within 30 days prior to surgery. During the screening visit, subjects will be assessed for any past or present medical conditions that in the opinion of the investigator would preclude them from study participation.

After the Informed Consent Form (ICF) is signed, a medical history, surgical history, physical examination, 12-lead electrocardiogram (ECG), vital sign measurements, alcohol breath test and urine drug screen, and clinical laboratory tests (hematology and chemistry) will be performed.

On Day 1, prior to the C-section, eligible subjects will be randomized in a 1:1:1 ratio into one of the three treatment groups listed below:

  • Group 1: 150 mcg Duramorph® (SOC arm)+ postoperative multi-modal pain regimen as defined in this protocol. No EXPAREL TAP infiltration following skin-incision closure.
  • Group 2: 50 mcg Duramorph + EXPAREL TAP infiltration following skin-incision closure + postoperative multi-modal pain regimen as defined in this protocol.
  • Group 3: EXPAREL TAP infiltration following skin-incision closure + postoperative multi-modal pain regimen as defined in this protocol. No Duramorph.

Rescue Medication will be provided, as needed, for all subjects.

Subjects will remain in the hospital for up to 72 hours after surgery.

Total opioid burden and Pain intensity scores using a 10 cm Visual Analog Scale (VAS) will be collected.

Daily pain intensity score (VAS) and all pain medications will be collected through Day 14.

A phone call will be made to each subject on Day 14 and Day 30.

02

Conditions studied

  • Elective Cesarean Section
  • Pain Management

Keywords

  • bupivacaine
  • EXPAREL
  • analgesic
  • TAP Block
  • C-Section
  • Cesarean Section
  • elective c-section
  • TAP
03

In context

Lead sponsor

Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females 18 years of age and older at screening.
  2. Term pregnancies of 37 to 42 weeks gestation, scheduled to undergo elective C-section.
  3. American Society of Anesthesiology (ASA) physical status 1, 2, or 3.
  4. Able to provide , adhere to the study visit schedule, and complete all study assessments.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who, in the opinion of the study site principal investigator, have a high-risk pregnancy.
  2. Subjects with a pregnancy-induced medical condition or complication.
  3. Subjects with 3 or more prior C-sections.
  4. Pre-pregnancy >50 kg/m2.
  5. Allergy, , intolerance, or to any of the study medications.
  6. Planned concurrent surgical procedure with the exception of salpingo-oophorectomy or tubal ligation.
  7. Severely impaired renal or hepatic function.
  8. Subjects at an increased risk for bleeding or a coagulation disorder.
  9. Concurrent painful physical condition that may require analgesic treatment in the postsurgical period for pain that is not strictly related to the surgery.
  10. medical disease in either the mother or baby that, in the opinion of the investigator, would make participation in a clinical study inappropriate.
  11. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
  12. Administration of an drug within 30 days or 5 elimination half-lives of such investigational drug.
  13. Previous participation in an EXPAREL study.
  14. Any clinically significant event or condition uncovered during the surgery that might render the subject medically unstable or complicate the subject's postsurgical course.
  15. Receives the epidural component of combined spinal epidural (CSE) anesthesia during the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
167 participants (actual)

Study arms

  • Active comparator
    Group 1 (Standard of Care Group)

    150 mcg Duramorph® + postoperative multi-modal pain regimen. No EXPAREL TAP infiltration

    Drug: 150 mcg Duramorph + multi-modal pain regimen

  • Experimental
    Group 2 (Duramorph + EXPAREL TAP)

    50 mcg Duramorph + EXPAREL TAP infiltration + postoperative multi-modal pain regimen.

    Drug: 50 mcg Duramorph+ EXPAREL + multi-modal pain regimen

  • Experimental
    Group 3 (EXPAREL TAP)

    EXPAREL TAP infiltration + postoperative multi-modal pain regimen. No Duramorph.

    Drug: Exparel TAP + multi-modal pain regimen

Interventions

  • Drug50 mcg Duramorph+ EXPAREL + multi-modal pain regimen

    Intrathecal injection of 50 mcg Duramorph + EXPAREL administered via TAP infiltration + multi-modal pain regimen.

  • Drug150 mcg Duramorph + multi-modal pain regimen

    Intrathecal injection of 150 mcg Duramorph + multi-modal pain regimen.

  • DrugExparel TAP + multi-modal pain regimen

    EXPAREL administered via TAP infiltration + multi-modal pain regimen.

06

What researchers measure

Primary outcomes

  1. Total Postsurgical Opioid Consumption Through 72 Hours

    To Compare total opioid consumption through 72 hours following EXPAREL infiltration into the Transversus abdominus plane (TAP) with SOC in subjects undergoing an elective C-section

    Time frame: Through 72 hours post-surgery

Secondary outcomes

  1. Percentage of Opioid-free Subjects

    Percentage of opioid-free subjects. LS Means probability from the logistic regression with treatment, site, age, and height as explanatory variables.

    Time frame: through 72 hours or hospital discharge, whichever came first

  2. Severity of Itching (Numeric Rating Scale Score)

    Severity of itching (Numeric Rating Scale score from 0(being none)-10(being the worst))

    Time frame: through 72 hours after surgery

  3. Opioid Related Symptom Distress Scale Score (ORSDS)

    The Opioid-Related Symptom Distress Scale (ORSDS) is a 4-point scale that evaluates 3 symptom distress dimensions (frequency, severity, bothersomeness) for 10 symptoms. The symptom-specific ORSDS is the average of the 3 symptom distress dimensions. The composite ORSDS is the average of 10 symptom-specific scores. Each question will receive a score from 0-4 the composite score for each subject is the average of all scores. A higher score indicates a worse outcome.

    Time frame: through 72 hours after surgery

07

Results

Posted Jul 18, 2022

Participant flow

Participant flow — Overall Study
MilestoneGroup 1 (Standard of Care Group)Group 2 (Duramorph + EXPAREL TAP)Group 3 (EXPAREL TAP)
Started565655
Completed534751
Not completed394
Withdrew: Protocol violation353
Withdrew: Delivered early010
Withdrew: Not suitable to proceed010
Withdrew: Difficult surgery001
Withdrew: Lost to follow-up010
Withdrew: Withdrawal by subject010

Outcome measures

PrimaryTotal Postsurgical Opioid Consumption Through 72 Hours

To Compare total opioid consumption through 72 hours following EXPAREL infiltration into the Transversus abdominus plane (TAP) with SOC in subjects undergoing an elective C-section

Time frame:
Through 72 hours post-surgery
Reported as:
Least squares mean · OMED mg
Total Postsurgical Opioid Consumption Through 72 Hours
OMED mgGroup 1 (Standard of Care Group)Group 2 (Duramorph + EXPAREL TAP)Group 3 (EXPAREL TAP)
Total Postsurgical Opioid Consumption Through 72 Hours69.3 ± 1.1536.1 ± 1.1622.1 ± 1.16
SecondaryPercentage of Opioid-free Subjects

Percentage of opioid-free subjects. LS Means probability from the logistic regression with treatment, site, age, and height as explanatory variables.

Time frame:
through 72 hours or hospital discharge, whichever came first
Reported as:
Number · percentage of participants, opioid free
Percentage of Opioid-free Subjects
percentage of participants, opioid freeGroup 1 (Standard of Care Group)Group 2 (Duramorph + EXPAREL TAP)Group 3 (EXPAREL TAP)
Percentage of Opioid-free Subjects22.428.830
SecondarySeverity of Itching (Numeric Rating Scale Score)

Severity of itching (Numeric Rating Scale score from 0(being none)-10(being the worst))

Time frame:
through 72 hours after surgery
Reported as:
Least squares mean · score on a scale
Severity of Itching (Numeric Rating Scale Score)
score on a scaleGroup 1 (Standard of Care Group)Group 2 (Duramorph + EXPAREL TAP)Group 3 (EXPAREL TAP)
Severity of Itching (Numeric Rating Scale Score)1.48 ± 0.1610.94 ± 0.1760.61 ± 0.167
SecondaryOpioid Related Symptom Distress Scale Score (ORSDS)

The Opioid-Related Symptom Distress Scale (ORSDS) is a 4-point scale that evaluates 3 symptom distress dimensions (frequency, severity, bothersomeness) for 10 symptoms. The symptom-specific ORSDS is the average of the 3 symptom distress dimensions. The composite ORSDS is the average of 10 symptom-specific scores. Each question will receive a score from 0-4 the composite score for each subject is the average of all scores. A higher score indicates a worse outcome.

Time frame:
through 72 hours after surgery
Reported as:
Least squares mean · score on a scale
Opioid Related Symptom Distress Scale Score (ORSDS)
score on a scaleGroup 1 (Standard of Care Group)Group 2 (Duramorph + EXPAREL TAP)Group 3 (EXPAREL TAP)
Opioid Related Symptom Distress Scale Score (ORSDS)0.33 ± 0.0550.23 ± 0.0530.35 ± 0.051

Adverse events

Collected over Adverse events and serious adverse events (SAEs) were recorded from the time the ICF was signed through Day 14.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1 (Standard of Care Group)0/53 (0%)2/53 (3.8%)43/53 (81.1%)
Group 2 (Duramorph + EXPAREL TAP)0/48 (0%)2/48 (4.2%)41/48 (85.4%)
Group 3 (EXPAREL TAP)0/52 (0%)2/52 (3.8%)30/52 (57.7%)
Most frequent serious events
Most frequent serious events
EventGroup 1 (Standard of Care Group)Group 2 (Duramorph + EXPAREL TAP)Group 3 (EXPAREL TAP)
DyspneaRespiratory, thoracic and mediastinal disorders0/531/480/52
ConstipationGastrointestinal disorders0/531/480/52
Postpartum hemorrhageInjury, poisoning and procedural complications0/530/481/52
Abdominal wall hematomaInjury, poisoning and procedural complications0/530/481/52
Incision Site PainInjury, poisoning and procedural complications1/530/480/52
Pre-eclampsiaPregnancy, puerperium and perinatal conditions1/530/480/52
Most frequent other events
Showing 10 of 11
Most frequent other events
EventGroup 1 (Standard of Care Group)Group 2 (Duramorph + EXPAREL TAP)Group 3 (EXPAREL TAP)
PruritusSkin and subcutaneous tissue disorders25/5328/4816/52
NauseaGastrointestinal disorders16/539/482/52
Pruritus generalisedSkin and subcutaneous tissue disorders9/536/484/52
ConstipationGastrointestinal disorders6/532/487/52
Abdominal distentionGastrointestinal disorders6/536/482/52
Incision site pruritusInjury, poisoning and procedural complications1/534/482/52
DizzinessNervous system disorders2/534/481/52
RashSkin and subcutaneous tissue disorders3/534/480/52
FlatulenceGastrointestinal disorders2/530/484/52
VomitingGastrointestinal disorders4/532/480/52

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group 1 (Standard of Care Group)Group 2 (Duramorph + EXPAREL TAP)Group 3 (EXPAREL TAP)Total
Mean33.2 ± 4.6734.1 ± 4.9332.7 ± 5.0333.3 ± 4.88
Sex: Female, Male
Sex: Female, Male(Participants)Group 1 (Standard of Care Group)Group 2 (Duramorph + EXPAREL TAP)Group 3 (EXPAREL TAP)Total
Female534852153
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1 (Standard of Care Group)Group 2 (Duramorph + EXPAREL TAP)Group 3 (EXPAREL TAP)Total
Hispanic or Latino65718
Not Hispanic or Latino464345134
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1 (Standard of Care Group)Group 2 (Duramorph + EXPAREL TAP)Group 3 (EXPAREL TAP)Total
American Indian or Alaska Native0000
Asian35816
Native Hawaiian or Other Pacific Islander0000
Black or African American53715
White413634111
More than one race1102
Unknown or Not Reported3339
Region of Enrollment
Region of Enrollment(participants)Group 1 (Standard of Care Group)Group 2 (Duramorph + EXPAREL TAP)Group 3 (EXPAREL TAP)Total
United States534852153
American Society of Anesthesiologists (ASA) Physical Status Classification
American Society of Anesthesiologists (ASA) Physical Status Classification(Participants)Group 1 (Standard of Care Group)Group 2 (Duramorph + EXPAREL TAP)Group 3 (EXPAREL TAP)Total
ASA I2035
ASA II474539131
ASA III431017
Body Mass Index (pre-pregnancy)
Body Mass Index (pre-pregnancy)(kg/m^2)Group 1 (Standard of Care Group)Group 2 (Duramorph + EXPAREL TAP)Group 3 (EXPAREL TAP)Total
Mean31.69 ± 5.09131.08 ± 5.18132.23 ± 6.17931.68 ± 5.490
08

Study locations

18 sites
  • Stanford University School of Medicine
    Stanford, California 94305, United States
  • University of Florida- Gainesville
    Gainesville, Florida 32610, United States
  • University of Florida college of Medicine - Jacksonville
    Jacksonville, Florida 32209, United States
  • Clinical Research Prime
    Idaho Falls, Idaho 83404, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08901, United States
  • St. Peter's University Medical Center
    New Brunswick, New Jersey 08901, United States
  • Columbia University Medical Center/NY Presbyterian Hospital
    New York, New York 10032, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Thomas Jefferson Medical Center
    Philadelphia, Pennsylvania 19107, United States
  • Magee-Women's Hospital of UPMC
    Pittsburgh, Pennsylvania 15213, United States
  • The University of Texas Medical Branch
    Galveston, Texas 77555-0877, United States
  • Inova Health System
    Falls Church, Virginia 22042, United States
  • West Virginia University
    Morgantown, West Virginia 86506, United States
09

References and documents

Publications

  • Habib AS, Nedeljkovic SS, Horn JL, Smiley RM, Kett AG, Vallejo MC, Song J, Scranton R, Bao X. Randomized trial of transversus abdominis plane block with liposomal bupivacaine after cesarean delivery with or without intrathecal morphine. J Clin Anesth. 2021 Dec;75:110527. doi: 10.1016/j.jclinane.2021.110527. Epub 2021 Oct 6. PubMed 34626927 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Jan 2020, 10 months.

Results were first posted in Jul 2022, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2018
First posted
Feb 26, 2019
StartActual
Mar 4, 2019
Primary completionActual
Jan 9, 2020
CompletionActual
Jan 16, 2020
Results first posted
Jul 18, 2022
Last update
Jul 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03853694
Responsible party
Sponsor
First posted
Feb 26, 2019
Start date
Mar 4, 2019
Primary completion
Jan 9, 2020
Completion
Jan 16, 2020
Results posted
Jul 18, 2022
Last update
Jul 18, 2022

Study contacts

Nayana Nagaraj, MD, PhD, MPH
study director · Pacira Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion